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Abstract
Background: Transforming growth factor beta 1 (TGF-β1) gene play an important role in the
acute myocardial infarction (AMI), however no investigation has been conducted so far in young
AMI patients.
In this study, we evaluated the influence of TGF-β1 polymorphisms/haplotypes on the onset and
progression of AMI in young Italian population.
Methods: 201 cases and 201 controls were genotyped for three TGF-β1 polymorphisms (G-800A,
C-509T and Leu10Pro). The main follow-up end-points (mean follow-up, 107 ± 49 months) were
death, myocardial infarction or revascularization procedures.
Results: Significant risk factors were smoking (p < 10-4), family history for coronary artery disease
(p < 10-4), hypercholesterolemia (p = 0.001) and hypertension (p = 0.002). The C-509T and
Leu10Pro polymorphisms showed significant differences (p = 0.026 and p = 0.004) between cases
and controls.
The most common haplotypes revealed a possible protective effect (GCT, OR 0.75, 95% CI 0.57–
0.99, p = 0.042) and an increased risk of AMI (GTC, OR 1.51, 95% CI 1.13–2.02, p = 0.005),
respectively.
No statistical differences were observed in genotype distribution in the follow-up study between
the two groups: 61 patients with subsequent events (13 deaths) and 108 without events.
Conclusion: Even though our results need to be further confirmed in larger studies, this is the
first study reporting on a possible role of TGFβ1 common haplotypes in the onset of AMI in young
patients.
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Background
AMI at young age (< 45 years) is a multifaceted disorder
characterized by low mortality rates, less extensive coro-
nary artery disease (CAD), good residual left ventricular
function, and a favourable prognosis [1]. In addition,
young patients show lower occurrence of diabetes and
hypertension, but in contrast family history of CAD,
hypercholesterolemia, and smoking are more frequent
[2].
Genes regulating vascular function, lipid metabolism,
coagulation, fibrinolysis and inflammation factors have
been only partially investigated in AMI at young age,
reporting controversial results [3]. Some polymorphisms
in prothrombin gene seem to be associated with increased
risk of AMI at young age and Factor VII Leiden polymor-
phisms seem to be protective, whereas contrasting results
have been reported for the polymorphism G894T in the
nitric oxide synthase (eNOS) gene and polymorphism
C677T in the 5,10-methylenetetrahydrofolate reductase
(MTHFR) gene.
A recent promising trend of research was the study of
genes involved in inflammatory response related to CAD
and atherosclerosis [4]. However, the role of TGF-β1
genetic variants in the occurrence of AMI at young age was
not investigated so far.
TGF-β1 is a cytokine expressed by a broad variety of cells,
including platelets, connective, haematopoietic and
endothelial tissue cells [5]. TGF-β1 is the most abundant
isoform of the TGFβ family, and it is a multifunctional
cytokine regulating cell growth, differentiation and matrix
production [6]. TGF-β1 has been found to enhance the
expression of mRNA encoding endothelin in vascular
endothelial cells [7] and the synthesis of extracellular
matrix components such as collagen, fibronectin, and
proteoglycan [8].
Recent evidence suggests that pathological misregulation
of the transforming growth factor-β (TGF-β) pathway
could be implicated in the development of several major
diseases, including myocardial infarction [9], fibrotic dis-
ease [10], and inflammation processes [4]. In particular,
higher levels of serum or plasma TGF-β1 have been
observed in subjects with hypertension, in association
with cardiac and renal disease [11,12] or in dilated cardi-
omyopathy [13], both exacerbated by smoke, although
leading to conflicting conclusions.
Even if a clear causative role of TGF-β1 was not demon-
strated, changes in the structure and activity of TGF-β1,
caused by genetic variants, could influence the biologic
processes involving the protein.
We selected three TGF-β1 variants, two of them (G-800A
and C-509T) being in the promoter region, near to the
consensus DR1 or DR5 nuclear hormone receptor binding
sites, crucial for influencing the TGF-β1 synthesis. The
third selected polymorphism Leu10Pro (T > C transition)
is located into the peptide signal sequence and could
interfere with its activity by influencing the transport of
the preprotein to the endoplasmic reticulum [14].
In the present study we evaluated the potential role of the
above genetic variants in the occurrence and the prognosis
of AMI at young age.
Methods
Patients and controls
The sample of cases was composed by 201 patients (age
40 ± 4 years), who satisfied the World Health Organiza-
tion criteria for the diagnosis of myocardial infarction
[15], and who were consecutively admitted between 1992
and 2005 to the Coronary Care Unit of the University Car-
diology Division of St. Giovanni Battista Hospital of Turin
[16].
The 201 patients were matched with healthy control sub-
jects, recruited by General Practitioners, by sex, diabetes
status and age (± 1 year). The study complies with the
Declaration of Helsinki and was approved by the Inter-
hospital Ethical Board, San Giovanni Battista/C.T.O./
C.R.F./Maria Adelaide hospitals (President of the Ethical
Board Prof. Alessandro Pileri). The subjects gave informed
consent and no sex-based or ethnic-based differences were
present, although most of them are of Caucasoid origins.
Information on the following conventional risk factors
were collected: age, sex, body mass index, smoking habits,
history of hypercholesterolemia (total cholesterol levels >
220 mg/dl or use of hypocholesterolemic drugs), diabetes
status, hypertension treatment [17], personal and family
history of CAD.
A positive family history was considered if the patient had
a first-degree relative with CAD at the age of ≤ 55 years for
men or at ≤ 65 years for women.
Patients with ascertained congenital hypercoagulable sta-
tus, with a proved disease limiting life expectance or with
declared cocaine abuse were excluded. Control subjects
with CAD and any neoplasm, cardiomyopathy or severe
illness limiting life expectance or refusing consent were
excluded.
Follow-up (mean 107 ± 49 months) was possible until
2005 for 169 cases (84% of the initial population study),
and was performed investigating new hospital admis-BMC Medical Genetics 2008, 9:13 http://www.biomedcentral.com/1471-2350/9/13
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sions, performing telephone interview of patients and
periodic ambulatory visits.
Endpoint events considered were death, new myocardial
infarction and revascularization procedure (angioplasty
or coronary artery bypass graft surgery) that occurred after
discharge from the index event.
Laboratory analyses
Blood samples were collected ≥ 6 hours after fasting and 3
months after the index AMI event to avoid influence of
acute event on lipid parameters. Total cholesterol, triglyc-
erides, high-density lipoprotein and low-density lipopro-
tein cholesterol, apolipoprotein B, and apolipoprotein A1
were measured by conventional methods of clinical
chemistry.
Genomic DNA was extracted from 200 μl of peripheral
blood lymphocytes according to a standard salting-out
method [18]. For the 3 polymorphisms, DNA were ampli-
fied by Polymerase Chain Reaction and digested with spe-
cific restriction endonucleases, as previously reported
[19].
Statistical analysis
We calculated allele and genotype frequencies of the G-
800A, C-509T and Leu10Pro polymorphisms by direct
gene counting; the chi-square statistics was used to test for
Hardy-Weinberg equilibrium.
Haplotype reconstruction and their frequencies were esti-
mated from genotypes data by using a Bayesian statistical
method based on the coalescence theory, implemented in
the PHASE package version 2.0 (default settings were
used).
Linkage disequilibrium parameters (D' and r2 statistics)
were calculated by the Haploview version 3.31 software.
A Pearson chi square test or Fisher exact test when appro-
priate (a P value ≤ 0.05 was considered significant) were
performed to compare the distribution of the patients and
control for each polymorphism and for each risk factor,
both in the acute and follow-up study.
A logistic regression analysis was performed to calculate
Odds Ratio (OR) and 95% Confidence Intervals (95%
CI), and adjusting genetic risks for smoking habits, family
history, hypercholesterolemia and hypertension. With
201 cases and 201 controls, a power of 80% and α = 0.05
we are able to detect an increase in OR = 1.7–2.24 depend-
ing on the allele frequencies of the three polymorphisms.
Cox regression was also performed for the follow-up anal-
ysis taking into account the time variable. All the analyses
were performed by the statistical package SPSS v.13.0.
Results
Prevalence of classical risk factors among cases and con-
trols are reported in Table 1.
We have found a statistically significant difference
between cases and controls for smoking (79.1% in cases
vs 59.7% in controls, p < 10-4) and familial history of CAD
(62.3% vs 20.2%, p < 10-4). Significant differences were
observed also for hypertension (33.9% vs 16.3%, p =
0.002) and for hypercolesterolemia (54.9% vs 35.7%, p =
0.001).
We genotyped three TGF-β1 polymorphisms in 201
young patients with diagnosed AMI and 201 matched
controls (mean age 40 ± 4 years, range 25–45 years). All
the polymorphisms were in Hardy-Weinberg equilibrium.
No statistical difference has been observed in the distribu-
tion of conventional risk factors by stratifying cases and
controls for genotypes (data not shown).
Table 1: Prevalence of main conventional risk factors in cases and controls.
Risk factors Cases N (%) Controls N (%) Total N (%) P value
Smoking Yes 148 (79.1) 74 (59.7) 222 (71.4) < 10-4
No 39 (20. 9) 50(40.3) 89 (28.6)
CAD familiarity Yes 119 (62.3) 20 (20.2) 139 (47.9) < 10-4
No 72 (37.7) 79 (79.8) 151 (52.1)
Hypertension Yes 64 (33.9) 15 (16.3) 79 (28.1) 0.002
No 125 (66.1) 77 (83.7) 202 (71.9)
Hypercolesterolemia Yes 107 (54.9) 41 (35.7) 148 (47.7) 0.001
No 88 (45.1) 74 (64.3) 162 (52.3)
P value = Fisher exact test.BMC Medical Genetics 2008, 9:13 http://www.biomedcentral.com/1471-2350/9/13
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The genotype frequencies (Table 2) appeared significantly
different between cases and controls for Leu10Pro (3 × 2
contingency table, p = 0.005), with a significant increased
risk as crude Odds Ratios for the CC vs TT genotype (OR
2.35, 95% CI 1.34–4.12, p = 0.003).
A borderline significance has been observed for C-509T
polymorphism (3 × 2 contingency table, p = 0.06), with
an interesting increased risk for the TT genotype vs the
wild-type CC homozygotes (OR 1.93, 95% CI 1.10–3.41,
p = 0.02). However, after Bonferroni correction only
Leu10Pro was still significant.
After adjusting for smoking habits, family history, hyper-
cholesterolemia and hypertension, results for C-509T and
Leu10Pro polymorphisms were no more significant
(Table 2).
No significant association has been observed for the three
TGF-β1 genotypes (Table 3) and for haplotypes (not
shown) in the follow-up analysis between the group of 61
patients with a second event after AMI and 108 patients
without other events both at univariate and multivariate
analysis.
No statistical significant association has been reported for
G-800A (p = 0.57). In fact, LD pairwise comparison
showed stronger significant values between C-509T and
Leu10Pro markers, but lower LD value between these two
single nucleotide polymorphisms and C-800A (C-800A/
G-509T = 0.02, G-800A/Leu10Pro = 0.03, C-509T/
Leu10Pro = 0.59, LD values referred to r2 statistic).
Haplotypes were reconstructed and the difference in their
distribution between case and control groups was investi-
Table 2: Allele and genotype frequency distribution among AMI cases and controls.
Polymorphism Genotype Cases (%) Controls (%) P value Crude ORs (95%CI) P value Adjusted ORs (95%CI) P value
G-800A GG 175 (87.1) 168 (83.6) a0.571 1 1
AG 25 (12.4) 31 (15.4) 0.774 (0.439–1.366) 0.377 0.645 (0.225–1.849) 0.414
AA 1 (0.5) 2 (1.0) 0.48 (0.043–5.343) 0.551 0.177 (0.002–2.721) 0.427
G/A 375/27 367/35 b0.290
C-509T CC 67 (33.3) 80 (39.8) a0.062 1
CT 87 (43.3) 92 (45.8) 1.129 (0.729–1.749) 0.586 1.365 (0.604–3.083) 0.454
TT 47 (23.4) 29 (14.4) 1.935 (1.100–3.406) 0.022 1.943 (0.754–5.003) 0.169
C/T 221/181 252/150 b0.026
Leu10Pro TT 55 (27.4) 69 (34.3) a0.005 1
CT 88 (43.8) 101 (50.2) 1.093 (0.693–1.723) 0.702 1.138 (0.481–2.693) 0.768
CC 58 (28.9) 31 (15.4) 2.347 (1.338–4.117) 0.003 1.589 (0.610–4.136) 0.343
T/C 198/204 239/163 b0.004
a Pearson chi square P value of the 3 × 2 contingency table; b Pearson chi square P value of the 2 × 2 contingency table. Crude and adjusted odds 
ratios (for smoking habits, family history, hypercholesterolemia and hypertension) and 95% CI are reported.
Table 3: Genotype frequency distribution among the two follow-up groups (events vs non events).
Polymorphism Genotype Events (%) No events (%) P value Crude ORs (95%CI) P value Adjusted ORs (95%CI) P value
G-800A GG 50 (82.0%) 97 (89.8%) 1 1
AG 11 (18.0%) 10 (9.3%) a0.196 2.134 (0.849–5.365) 0.107 2.145 (0.850–5.412) 0.106
AA 0 (0%) 1 (0.9%) 0.000 (0.000) 1 0.000 (0.000) 1
C-509T CC 19 (31.1%) 40 (37.0%) 1 1
CT 30 (49.2%) 39 (36.1%) a0.241 1.619 (0.785–3.342) 0.192 1.839 (0.801–4.226) 0.151
TT 12 (19.7%) 29 (26.9%) 0.871 (0.366–2.072) 0.755 1.024 (0.425–2.470) 0.957
Leu10Pro TT 14 (23.0%) 32 (29.4%) 1 1
CT 26 (42.6%) 45 (43.4%) a0.588 1.321 (0.598–2.916) 0.491 1.434 (0.639–3.215) 0.382
CC 21 (34.4%) 31 (27.2%) 1.548 (0.670–3.577) 0.306 1.711 (0.728–4.022) 0.218
a Pearson chi square P value of the 3 × 2 contingency table. Crude and adjusted odds ratios (for family history) and 95% CI are reported.BMC Medical Genetics 2008, 9:13 http://www.biomedcentral.com/1471-2350/9/13
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gated (Table 4). A total of seven haplotypes, with two of
them being the most prevalent, were estimated in both
groups.
Only the two most common haplotypes (GCT and GTC)
showed statistical differences between the two groups.
The frequency of the GCT haplotype carrying the wild type
allele at both C-509T and Leu10Pro polymorphism was
higher in the control groups (48.7%) than in cases
(41.6%) (OR 0.75, 95% CI 0.57–0.99; p = 0.042). On the
contrary, the GTC haplotype, carrying the two variant alle-
les at the above positions, had a higher frequency in the
case group (40.7% vs 31.2% in controls; OR 1.51, 95% CI
1.13–2.02, p = 0.005). Both haplotypes carry the wild-
type allele of the G-800A polymorphism.
Out of the 61 patients with subsequent events, we regis-
tered 13 deaths. Most of the classical risk factors were not
considered in the follow-up study due to the adoption of
controlled therapies. Cox regression was also performed
in the follow-up phase but no significance was observed
(data not shown).
Discussion
To our knowledge, this is the first study investigating the
possible involvement of TGF-β1 gene in the occurrence
and the prognosis of AMI at young age, although an asso-
ciation has been already described in older patients [9].
TGF-β1 is involved in many biological processes and mis-
regulations in the TGF-β pathways have been investigated
in pathologic states such as cardiac hypertrophy [20],
atherosclerosis [21] and inflammation processes [4].
Increased TGF-β1 mRNA expression was also observed in
human restenotic lesions [22]; on the other hand, it was
postulated that increased expression of TGF-β1 at the
artery wall level, by inhibition of vascular smooth muscle
cells (VSMC), could consequently inhibit the accumula-
tion of lipid in vessel wall [14].
Various TGFβ1 polymorphisms were so far investigated to
ascertain their possible involvement in the occurrence of
several cardiovascular diseases [23], and they were
selected on the basis of their peculiar localization. Even if
the relevance of other polymorphisms, as Arg25Pro, has
been ascertained in the cardiovascular studies, in our pre-
liminary study we focused only on some of them.
The G-800A variant, occurring at 800 base pairs upstream
the 5' principal transcription start site, is located in a cru-
cial consensus CREB half-site [24]; the A allele could
inhibit the binding to the transcription factors CRE-BP,
which appeared implicated in the regulation of other
TGFβ-gene family elements. As the G-800A, so the C-509T
variant is a promoter polymorphism, located in a tran-
scription factor consensus binding site; the T allele could
affect the TGFβ1 expression levels [14]. Both polymor-
phisms are situated close to the consensus DR1 or DR5
nuclear hormone receptor binding sites, known as crucial
sequences in the regulation of the TGF-β1 synthesis in
vitro [24] and in vivo [24].
The coding Leu10Pro polymorphism, located in the
codon 10 of the gene, fall in the signal peptide sequence,
necessary to address the synthesized protein to the endo-
plasmic reticulum. In the past years, consistent conclu-
sions deriving from the study of these TGF-β1 variants
were produced, even if the results appear controversial.
In a study of Yokota et al. [14] it was reported a correlation
of the wild type allele of C-509T with low TGF-β1 plas-
matic concentration. According to these results, the T
allele of C-509T was found associated with higher circu-
lating TGF-β1 levels [24], often related to hypertension,
and in association with cardiac disease [12] or to dilated
cardiomyopathy [13]. The C-509T polymorphism (and its
haplotypes) was also recently found associated with myo-
cardial infarction in men [9], even after adjustment for
smoking habits, age, hypertension, diabetes and hyperc-
holesterolemia. This result is in agreement with a possible
described correlation between genetic variants in the
Table 4: Estimated haplotype frequency distribution in case and control groups.
Haplotype Cases (%) Controls (%) Chi square P values OR (95% CI)
GCT 167 (41.6) 196 (48.7) 4.143 0.042 0.75 (0.57–0.99)
GTC 164 (40.7) 125 (31.2) 7.863 0.005 1.51 (1.13–2.02)
GCC 34 (8.6) 28 (7.0) 0.695 NS 1.25 (0.74–2.09)
ACT 21 (5.3) 25 (6.3) 0.416 NS 0.82 (0.45–1.49)
GTT 10 (2.6) 18 (4.4) 2.281 NS 0.55 (0.25–1.21)
ATC 5 (1.2) 8 (1.9) 0.651 NS 0.63 (0.20–1.97)
ATT 1 (0.2) 1 (0.4) 0.266 NS 0.48 (0.03–8.48)
Total 402 402
Haplotype = The haplotypes were defined with polymorphisms in the following order: G-800A, C-509T and Leu10Pro.BMC Medical Genetics 2008, 9:13 http://www.biomedcentral.com/1471-2350/9/13
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inflammatory genes and the risk modulation of ischaemic
heart disease [4]. Moreover, the Leu10Pro variant [14] was
found in association with myocardial infarction (MI) in
Japanese patients (OR = 3.5 p < 0.0001), although a pre-
vious European study [25] did not show any association
between this polymorphism and MI.
We have found that both C-509T and Leu10Pro polymor-
phisms could modulate genetic susceptibility to juvenile
AMI, whereas no significant differences was observed for
G-800A, in agreement with some studies [9,14], but not
with others [25].
Contrasting results could be partly explained by the heter-
ogeneity of the studies, due both to different prevalence of
classical risk factors or to different genetic and ethnic
backgrounds.
Our results on C-509T and Leu10Pro polymorphisms
seem to support the possible relevance of this gene. In fact
Leu10Pro does not change the amino-acidic polarity [25],
but it is located in a crucial position [14], as above men-
tioned.
The relevance of C-509T and Leu10Pro is also strength-
ened by the haplotype results indicating a possible
increased risk of AMI conferred by the GTC haplotype and
a protective effect of the GCT haplotype. According to
these results the putative "protective" haplotype (GCT)
carries both the C-509T and Leu10Pro wild type alleles,
whereas the putative "predisposing" haplotype GTC car-
ries the mutated alleles. Moreover the two haplotypes
were the most common both in cases and in controls, sup-
porting the idea that common variants/haplotypes could
be really important in determining common diseases
[26]. Although the above described crucial location of the
G-800A variant in the genome sequence, we did not
observe a significant association between G-800A and
AMI.
The lack of significant results for TGF-β1 polymorphisms/
haplotypes in the follow-up analysis seems to suggest that
different genetic mechanisms could be responsible for the
progression of AMI.
Conclusion
In conclusion, although it is clear that AMI is a multifac-
torial disease due to the combination of many genetic and
well known environmental risk factors, this is the first
study reporting on a significant association between TGF-
β1 polymorphisms/haplotypes and the occurrence of AMI
at young age.
Although these results warrant further investigation on
larger sample size and in-depth biochemical analysis
relating, for example, haplotypes to the TGF-β1 serum lev-
els, they indicate also the need to better clarify the role of
TGF-β pathway in AMI.
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